Page results
-
This page tells you about the procedure known as a renal cryoablation. It explains what is involved and what the possible risks are.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
Breathing aids developed by engineers at UCL, UCLH and Mercedes-AMG High Performance Powertrains have been delivered to 40 NHS hospitals across the country.
-
Patients recovering from coronavirus have spoken movingly about the physical and emotional legacy of the disease.
-
The children and young people's division at UCLH are running two events for young people aged 13 - 24 years.
-
The special haematology service provides a comprehensive investigation of haemolytic amaemia, haemoglobinopathies and red cell enzymopathy.
-
A UCLH/UCL clinical trial of a personalised therapy for blood cancer has been expanded, meaning new groups of patients with a wider range of blood cancers are now receiving the treatment.
-
This leaflet has written by the administration team at the National Hospital for Neurology and Neurosurgery for outpatients.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
This page is for patients receiving steroids for immunotherapy toxicity.
File results
-
FOI/2024/0703 - Neurofibromatosis type 1 treatment/ volume of medication dispensed
-
FOI/2024/0704 - Contingencies to support visitors/ patients/ contractors witnessing a distressing event
-
FOI/2024/0709 - Number of dilation and curettage operations for miscarriages 2019-2024
-
FOI/2024/0712 - Occupational health services, spend/ in-house/ outsourced 2021/22-2023/24
-
FOI/2024/0716 - Toxicological screening/ testing/ training and information to patients
-
FOI/2024/0718 - Mental health/ electronic health records software/ dermatology screening/ imaging services/ medical devices for wound care
-
FOI/2024/0719 - Tenders and prices for interpretation services
-
FOI/2024/0720 - Motion picture licensing corporation
-
FOI/2024/0721 - New biologic and targeted medications/ treatment within dermatology
-
FOI/2024/0734 - Treatment and management of patients with Lupus 2023